Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) – Pipeline Review, H2 2016’, provides in depth analysis on Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted pipeline therapeutics.

The report provides comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)

The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects

The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Momenta Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) Overview 6

Therapeutics Development 7

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Products under Development by Stage of Development 7

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Products under Development by Therapy Area 8

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Products under Development by Indication 9

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Pipeline Products Glance 11

Early Stage Products 11

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Products under Development by Companies 12

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Products under Development by Universities/Institutes 14

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Companies Involved in Therapeutics Development 22

Momenta Pharmaceuticals, Inc. 22

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Drug Profiles 23

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

CM-30119 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Drugs to Inhibit Heparanase for Oncology - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

necuparanib - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

roneparstat - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecule to Inhibit Heparanase for Lung Cancer and Pancreatic Cancer - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Dormant Projects 34

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Discontinued Products 36

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) - Featured News & Press Releases 37

Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis 37

Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 37

May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 38

Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 39

Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 39

Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 39

May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 40

Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer 41

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer 41

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer 42

Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer 43

May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001 43

Jul 02, 2012: Momenta Pharma Doses First Patient With M402 In Phase I/II Clinical Trial In Metastatic Pancreatic Cancer 44

Jun 04, 2012: Momenta Pharma Presents Positive Preclinical Results Of M402 In Combination With Gemcitabine At ASCO 2012 Annual Meeting 45

Jun 20, 2011: Momenta Announces Publication Of Preclinical Results Of Oncology Drug M402 In PLoS One 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 22

Dormant Projects, H2 2016 34

Dormant Projects (Contd..1), H2 2016 35

Discontinued Products, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports